| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-645 | |
| Phytochemical name or plant extracts | Bowman-Birk protease inhibitor | |
| PMID | 34121699 | |
| Literature evidence | CONCLUSION: According to our results, BBI could inhibit autophagy and induce apoptosis in MDA-MB-231 cell line. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Protease inhibitor | |
| Source of phytochemicals or plant Extracts | Glycine max | |
| Geographical availability | Amur, China North-Central, China South-Central, China Southeast, Hainan, Inner Mongolia, Japan, Khabarovsk, Korea, Laos, Manchuria, Nansei-shoto, Primorye, Qinghai, Taiwan, Thailand, Tibet, Vietnam, Xinjiang | |
| Plant parts | NA | |
| Other cancers | Breast cancer | |
| Target gene or protein | Atg5, Beclin-1, LC 3-II, Sequestosome1, Bax, Bcl-2 | |
| Gene or Protein evidence | The results of real-time reverse transcription-PCR exhibited that BBI altered the expression of Atg5, Beclin1, light chain 3-II, and sequestosome1 and increased the Bax/Bcl2 ratio in MDA-MB-231 cell line. | |
| Target pathways | NA | |
| IC50 | 200 μg/mL against MDA-MB-231 | |
| Potency | MTT results revealed that BBI inhibited the cell growth of MDA-MB-231 cell line in a dose-dependent manner, with an IC50 of 200 μg/mL. | |
| Cell line/ mice model | MDA-MB-231 | |
| Additional information | According to our results, BBI could inhibit autophagy and induce apoptosis in MDA-MB-231 cell line. Thus, BBI may be used as a therapeutic drug in the treatment of breast cancer whether alone or with chemotherapeutic drugs | |
| PubChem ID | NA | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:60450240-2 | |
| Safety | NA |